EAB 318
Latest Information Update: 21 Mar 2002
Price :
$50 *
At a glance
- Originator Wyeth
- Class Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 21 Mar 2002 Discontinued - Preclinical for Stroke in USA (unspecified route)
- 23 Nov 2000 Preclinical development for Stroke in USA (Unknown route)